ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
ARch Biopartners Inc (QB)

ARch Biopartners Inc (QB) (ACHFF)

1.38
0.04
(2.99%)
Closed 05 January 8:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.38
Bid
1.00
Offer
2.00
Volume
13,900
1.34 Day's Range 1.38
0.8925 52 Week Range 1.88
Market Cap
Previous Close
1.34
Open
1.36
Last Trade
100
@
1.38
Last Trade Time
Financial Volume
US$ 18,934
VWAP
1.3621
Average Volume (3m)
11,518
Shares Outstanding
64,650,633
Dividend Yield
-
PE Ratio
-38.83
Earnings Per Share (EPS)
-0.05
Revenue
1.98M
Net Profit
-3.33M

About ARch Biopartners Inc (QB)

Sector
Coml Physical, Biologcl Resh
Industry
Advertising Agencies
Headquarters
Toronto, Ontario, Can
Founded
2010
ARch Biopartners Inc (QB) is listed in the Coml Physical, Biologcl Resh sector of the OTCMarkets with ticker ACHFF. The last closing price for ARch Biopartners (QB) was US$1.34. Over the last year, ARch Biopartners (QB) shares have traded in a share price range of US$ 0.8925 to US$ 1.88.

ARch Biopartners (QB) currently has 64,650,633 shares in issue. The market capitalisation of ARch Biopartners (QB) is US$86.63 million. ARch Biopartners (QB) has a price to earnings ratio (PE ratio) of -38.83.

ACHFF Latest News

Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher

This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial to Treat Complications from Covid-19

TORONTO, Canada -- November 5, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that...

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

TORONTO, Ontario, CANADA -- October 16, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF...

Arch Biopartners submits IND to the FDA for COVID-19 Phase II trial to prevent organ inflammation.

TORONTO, Canada -- June 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company...

Arch Biopartners Receives Health Canada Approval for COVID-19 Phase II Human Trial

TORONTO, Canada -- May 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...

Arch Biopartners Applies to Health Canada to Conduct COVID19 Phase II Human Trial to Prevent Lung and Kidney Inflammation

TORONTO, Canada -- April 24, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...

Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology

Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology TORONTO, ONTARIO--(Marketwired - May 29, 2014) - Arch Biopartners Inc (Arch) or (the Company...

Arch Biopartners Appoints Claude Allary to Board of Directors

Arch Biopartners Appoints Claude Allary to Board of Directors TORONTO, ONTARIO--(Marketwired - Apr 17, 2014) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced...

Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections

Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections TORONTO, ONTARIO--(Marketwired - Mar 28, 2014) - Arch Biopartners Inc...

Arch Biopartners Completes Private Placement

Arch Biopartners Completes Private Placement TORONTO, ONTARIO--(Marketwired - Mar 25, 2014) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced today it has...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.086.153846153851.31.381.24811688251.30173626CS
40.0080.5830903790091.3721.3851.1128221.2471342CS
120.04993.751597624241.33011.52251.1115181.35566604CS
260.1613.11475409841.221.52250.892595261.27732955CS
520.28826.37362637361.0921.880.8925133761.36140171CS
156-1.42-50.71428571432.83.380.72128331.49908925CS
2600.63585.23489932890.7454.130.525132371.5206613CS

ACHFF - Frequently Asked Questions (FAQ)

What is the current ARch Biopartners (QB) share price?
The current share price of ARch Biopartners (QB) is US$ 1.38
How many ARch Biopartners (QB) shares are in issue?
ARch Biopartners (QB) has 64,650,633 shares in issue
What is the market cap of ARch Biopartners (QB)?
The market capitalisation of ARch Biopartners (QB) is USD 86.63M
What is the 1 year trading range for ARch Biopartners (QB) share price?
ARch Biopartners (QB) has traded in the range of US$ 0.8925 to US$ 1.88 during the past year
What is the PE ratio of ARch Biopartners (QB)?
The price to earnings ratio of ARch Biopartners (QB) is -38.83
What is the cash to sales ratio of ARch Biopartners (QB)?
The cash to sales ratio of ARch Biopartners (QB) is 65.15
What is the reporting currency for ARch Biopartners (QB)?
ARch Biopartners (QB) reports financial results in CAD
What is the latest annual turnover for ARch Biopartners (QB)?
The latest annual turnover of ARch Biopartners (QB) is CAD 1.98M
What is the latest annual profit for ARch Biopartners (QB)?
The latest annual profit of ARch Biopartners (QB) is CAD -3.33M
What is the registered address of ARch Biopartners (QB)?
The registered address for ARch Biopartners (QB) is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1
What is the ARch Biopartners (QB) website address?
The website address for ARch Biopartners (QB) is archbiopartners.com
Which industry sector does ARch Biopartners (QB) operate in?
ARch Biopartners (QB) operates in the ADVERTISING AGENCIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EGIOQEdgio Inc (CE)
US$ 0.01
(999,900.00%)
584
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.008
(799,900.00%)
477
THCBFTHC Biomed International Limited (CE)
US$ 0.001
(99,900.00%)
100
AEORFAEON REIT Investment Corporation (PK)
US$ 796.08
(26,436.00%)
1
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0.0002
(19,900.00%)
225
UFABQUnique Fabricating Inc (CE)
US$ 0.000001
(-99.98%)
102.53k
VICFFVice Health and Wellness Inc (CE)
US$ 0.000001
(-99.97%)
996
SAFSSafer Shot Inc (CE)
US$ 0.000001
(-99.93%)
2.54M
ERFBERF Wireless Inc (CE)
US$ 0.0001
(-99.89%)
99.77k
ARVLFArrival (CE)
US$ 0.0002
(-99.60%)
42.86k
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0038
(52.00%)
608.97M
HMBLHUMBL Inc (PK)
US$ 0.0009
(0.00%)
546.25M
PHILPHI Group Inc (PK)
US$ 0.0003
(0.00%)
501.07M
CBIACanopus Biopharma Inc (PK)
US$ 0.0002
(100.00%)
281.95M
RDARRaadr Inc (PK)
US$ 0.00125
(-10.71%)
169.44M

ACHFF Discussion

View Posts
mick mick 1 year ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 1 year ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 1 year ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 1 year ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 1 year ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 1 year ago
ACHFF
ARch Biopartners Inc (QB)
1.52
0.001 (0.07%)
Volume: 23,900
Day Range: 1.515 - 1.53
Last Trade Time: 3:52:20 PM EDT
πŸ‘οΈ0
mick mick 1 year ago
ACHFF
ARch Biopartners Inc (QB)
1.57
0.01 (0.64%)
Volume: 11,500
Day Range: 1.565 - 1.5801
Last Trade Time: 3:53:15 PM EDT
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.50
0.00 (0.00%)
Volume: 18,400
Day Range: 1.495 - 1.5101
Last Trade Time: 3:58:44 PM EDT
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.38
-0.07 (-4.83%)
Volume: 11,400
Day Range: 1.38 - 1.45
Last Trade Time: 3:53:41 PM EDT
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.52
-0.01 (-0.65%)
Volume: 43,700
Day Range: 1.48 - 1.531
Last Trade Time: 3:57:08 PM EDT
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.60
0.00 (0.00%)
Volume: 38,976
Day Range: 1.5925 - 1.61
Last Trade Time: 3:54:50 PM EDT
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.5602
0.00 (0.00%)
Volume:
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
1.70
-0.14 (-7.61%)
Volume: 4,500
Day Range: 1.69 - 1.72
Last Trade Time: 3:52:38 PM EST
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
2.00
0.00 (0.00%)
Volume: 7,047
Day Range: 2.00 - 2.024
Last Trade Time: 3:51:23 PM EST
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
2.0973
0.0272 (1.31%)
Volume: 2,000
Day Range: 2.092 - 2.0973
Last Trade Time: 2:58:43 PM EST
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
2.37
0.034 (1.46%)
Volume: 15,670
Day Range: 2.272 - 2.37
Bid: 1.80
Ask: 2.57
Last Trade Time: 3:59:02 PM EDT
Total Trades: 14
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
2.55
-0.0832 (-3.16%)
Volume: 1,000
Day Range: 2.55 - 2.55
Bid: 1.62
Ask: 3.63
Last Trade Time: 3:48:22 PM EDT
Total Trades: 2
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 2 years ago
ACHFF
ARch Biopartners Inc (QB)
2.71
-0.0224 (-0.82%)
Volume: 2,400
Day Range: 2.7002 - 2.71
Bid: 0.6637
Ask: 3.10
Last Trade Time: 10:15:11 AM EDT
Total Trades: 8
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.3545 ? 0.0145 (0.62%)
Volume: 500 @06/03/22 11:50:48 AM EDT
Bid Ask Day's Range
2.28 2.37 2.3545 - 2.3545
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.3545 ? 0.0145 (0.62%)
Volume: 500 @06/03/22 11:50:48 AM EDT
Bid Ask Day's Range
2.28 2.37 2.3545 - 2.3545
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
3.07 ? -0.04 (-1.29%)
Volume: 1,200 @04/29/22 3:10:21 PM EDT
Bid Ask Day's Range
2.1 4.22 3.07 - 3.07
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.63 ? 0.02 (0.77%)
Volume: 2,500 @03/11/22 3:56:45 PM EST
Bid Ask Day's Range
1.78 3.57 2.63 - 2.66
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.86 ? 0.01201 (0.42%)
Volume: 7,600 @02/04/22 3:46:54 PM EST
Bid Ask Day's Range
2.8 2.87 2.815 - 2.86
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 3 years ago
https://www.otcmarkets.com/stock/ACHFF
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.57 ? -0.03 (-1.15%)
Volume: 54,740 @11/05/21 3:59:41 PM EDT
Bid Ask Day's Range
1.45 2.58 2.402 - 2.65
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
2.57 ? -0.03 (-1.15%)
Volume: 54,740 @11/05/21 3:59:41 PM EDT
Bid Ask Day's Range
1.45 2.58 2.402 - 2.65
ACHFF Detailed Quote
πŸ‘οΈ0
dayneyus dayneyus 3 years ago
PhaseII Clinical trail Data locked end June, start of data analysis in late July
We should be hearing results very soon!

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (β€œArch” or the β€œCompany”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review.

After the recruitment of the last patient into the trial in early May, the Company’s Phase II data team reconciled the patient data collected from the seven clinical sites that participated in the trial. The database containing the trial data was then locked at the end of June, which enabled the start of data analysis in late July. All of the Phase II clinical sites in Canada, the U.S. and Turkey have been officially closed.
πŸ‘οΈ0
dayneyus dayneyus 3 years ago
In Phase II of covid19 clinical trails
https//clinicaltrails.gov/ct2/show/ntc04402957

From8K period ending 06/30/21
ARCH BIOPARTNERS INC.
Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended June 30, 2021 and 2020 (Unaudited - See Notice of No Auditor Review)
1. DESCRIPTION OF OPERATIONS
Arch Biopartners Inc. (the β€œCompany”) is a portfolio based biotechnology company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The Company works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

At present, the Company is focused on the clinical development of its lead drug candidate Metablok TM.
β€’ Metablok TM - or β€˜LSALT peptide’, has the potential to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys which often results in organ damage or failure, including in the case of sepsis and COVID-19;

The Company has three additional technology platforms in its portfolio under development:
β€’ AB569 - a new drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily in the lungs, and wounds;

β€’ Borg: Peptide-Solid Surface Interface - binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and reduce corrosion; and

β€’ MetaMx TM - proprietary synthetic molecules that target brain tumour initiating cells and invasive glioma cells.
The Company owns, or has exclusive licensing rights on the intellectual property ("IP") emanating from the programs listed above.
The corporate headquarters are located in Toronto, Ontario.
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
1.38 ? 0.05 (3.76%)
Volume: 6,565 @09/22/21 2:14:18 PM EDT
Bid Ask Day's Range
1.08 2.03 1.35 - 1.38
ACHFF Detailed Quote
πŸ‘οΈ0
2019Champs 2019Champs 3 years ago
This has really taken off. Otc volume is growing. So is the tsx volume. This one's going to do really well folks. I expect a 10 bagger from here minimum.
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
1.4592 ? 0.1092 (8.09%)
Volume: 93,641 @08/13/21 3:58:41 PM EDT
Bid Ask Day's Range
1.42 1.49 1.36 - 1.5
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
1.062 ? 0.02 (1.92%)
Volume: 7,000 @07/09/21 3:10:13 PM EDT
Bid Ask Day's Range
1.01 1.08 1.04 - 1.062
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 3 years ago
ARch Biopartners Inc (ACHFF)
1.062 ? 0.02 (1.92%)
Volume: 7,000 @07/09/21 3:10:13 PM EDT
Bid Ask Day's Range
1.05 1.07 1.04 - 1.062
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.04 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
1.1 1.13 - - -
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 4 years ago


πŸ‘οΈ0
mick mick 4 years ago
I AGREE, YES 'Arch Biopartners Inc. (ACHFF)'
πŸ‘οΈ0
2019Champs 2019Champs 4 years ago
Are you buying? These are great prices. This is an absolute gift at these prices. Low volume. 1 big seller with million+ shares was offloading otherwise it should be trading at $2.50+. I feel really strong about phase 2. All signs are pointing to a good result. Phase 2 should be done in a few weeks as well! This is a 10 bagger in the making. Minimum.
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.00999 ? 0.01869 (1.89%)
Volume: 500 @04/30/21 2:47:05 PM EDT
Bid Ask Day's Range
0.6691 1.1 1.00999 - 1.00999
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.1 ? 0.04 (3.77%)
Volume: 550 @04/16/21 3:51:21 PM EDT
Bid Ask Day's Range
0.8262 3.12 1.1 - 1.1
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.0 ? -0.001 (-0.10%)
Volume: 125 @02/19/21 11:50:08 AM EST
Bid Ask Day's Range
0.75 1.03 1.0 - 1.0
ACHFF Detailed Quote
πŸ‘οΈ0
mick mick 4 years ago
https://otcbb.swingtradebot.com/equities/ACHFF
πŸ‘οΈ0
mick mick 4 years ago
https://pennystocks.news/otc/?symbol=ACHFF
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.16641 ? 0.0 (0.00%)
Volume: 5 @12/07/20 10:17:36 AM EST
Bid Ask Day's Range
1.13 1.16 - - -
ACHFF Detailed Quote
πŸ‘οΈ0
AlwaysKing AlwaysKing 4 years ago
πŸ‘οΈ0
2019Champs 2019Champs 4 years ago
Lmao tsnp is a pump n dump. I doubled my money and bought more arch. You should do the same.
πŸ‘οΈ0
AlwaysKing AlwaysKing 4 years ago
UNLIKE THE RUNNER WE FOUND IN TSNP, ACHFF SURE TOOK A SHIT ON YOU DIDN'T IT?
πŸ‘οΈ0
mick mick 4 years ago
ARch Biopartners Inc (ACHFF)
1.25819 ? 0.03819 (3.13%)
Volume: 1,100 @10/23/20 12:34:42 PM EDT
Bid Ask Day's Range
1.22 1.28 1.254 - 1.26
ACHFF Detailed Quote
πŸ‘οΈ0
2019Champs 2019Champs 4 years ago
Here are some links to the science:

https://www.cell.com/action/showPdf?pii=S0092-8674%2819%2930782-2

Webinar from couple of months ago:

https://zoom.us/rec/play/E3gBfzmmLQxW7REF-lo_sCBgfFTUYNb4RVEJ07Bqn1YON9BYH6iMrfY-pRhC-gI8vHGUke9CDgo9N1yJ.Xw6L63LsOdGdNOqz?startTime=1597762652000&_x_zm_rtaid=QM8d4WVVQZmMF1e0M9fkNQ.1602875790298.1b21cd13b51261456df8fa4dbba328a1&_x_zm_rhtaid=746

I dont evaluate science but from what i have gathered from people that do is that Cilastatin and the pipeline appears to be good without any red flags and the drug has the potential to be extended as treatment for colorectal carcinoma and acute lymphoid leukemia as well.

Management team is excellent. They have guys on the board who have sold companies for billions of dollars in the past (patrick vink & adrian haigh)

0 outstanding warrants

Positive phase 2 news can really move this thing. Exciting times thats for sure
πŸ‘οΈ0
Ecomike Ecomike 4 years ago
Not much of video person, but if you have research paper DD on what ACHFF is doing, or DD papers you have found on the market size, applications and Bio-chem tech being used here I would love to have it. Thanks
πŸ‘οΈ0